Aeterna Zentaris Inc. completed a full review of data from its confirmatory phase III trial of oral Macrilen (macimorelin) for use as a growth hormone stimulation test to assess growth hormone deficiency in adults (AGHD) and concluded the data were sufficient to make a second run at registration with the FDA. In 2014, the agency issued a complete response letter (CRL) on the new drug application.